WO2003062415A3 - Transgenic animal comprising intracellular immunoglobins for xenotransplantation - Google Patents

Transgenic animal comprising intracellular immunoglobins for xenotransplantation Download PDF

Info

Publication number
WO2003062415A3
WO2003062415A3 PCT/IB2003/000653 IB0300653W WO03062415A3 WO 2003062415 A3 WO2003062415 A3 WO 2003062415A3 IB 0300653 W IB0300653 W IB 0300653W WO 03062415 A3 WO03062415 A3 WO 03062415A3
Authority
WO
WIPO (PCT)
Prior art keywords
xenotransplantation
intracellular
immunoglobins
transgenic animal
production
Prior art date
Application number
PCT/IB2003/000653
Other languages
French (fr)
Other versions
WO2003062415A2 (en
Inventor
Dubravka Drabek
Sylvia Dekker
Franklin Gerardus Grosveld
Original Assignee
Erasmus University
Dubravka Drabek
Sylvia Dekker
Franklin Gerardus Grosveld
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erasmus University, Dubravka Drabek, Sylvia Dekker, Franklin Gerardus Grosveld filed Critical Erasmus University
Priority to CA002474030A priority Critical patent/CA2474030A1/en
Priority to AU2003237975A priority patent/AU2003237975A1/en
Priority to EP03731802A priority patent/EP1470222A2/en
Publication of WO2003062415A2 publication Critical patent/WO2003062415A2/en
Publication of WO2003062415A3 publication Critical patent/WO2003062415A3/en
Priority to US10/894,194 priority patent/US20050108780A1/en
Priority to US11/372,250 priority patent/US20060150261A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies

Abstract

A transgenic organism is provided comprising a polynucleotide construct encoding an intracellular antibody which disrupts the catalysis of the production of the xenoantigen galactose α 1,3 galactose and/or a polynucleotide construct which encodes an intracellular antibody which binds pecifically to a retrovirus protein, such as a PERV particle protein. Also described are mthods for the production of such organisms. Cells, tissues and organs of the transgenic organism may be used in xenotransplantation.
PCT/IB2003/000653 2002-01-24 2003-01-24 Transgenic animal comprising intracellular immunoglobins for xenotransplantation WO2003062415A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002474030A CA2474030A1 (en) 2002-01-24 2003-01-24 Transgenic animal comprising intracellular immunoglobins for xenotransplantation
AU2003237975A AU2003237975A1 (en) 2002-01-24 2003-01-24 Transgenic animal comprising intracellular immunoglobins for xenotransplantation
EP03731802A EP1470222A2 (en) 2002-01-24 2003-01-24 Transgenic animal comprising intracellular immunoglobins for xenotransplantation
US10/894,194 US20050108780A1 (en) 2002-01-24 2004-07-19 Intracellular antibodies for a retrovirus protein
US11/372,250 US20060150261A1 (en) 2002-01-24 2006-03-09 Intracellular antibodies for a retrovirus protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0201611.1 2002-01-24
GBGB0201611.1A GB0201611D0 (en) 2002-01-24 2002-01-24 Transgenic animal

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/894,194 Continuation US20050108780A1 (en) 2002-01-24 2004-07-19 Intracellular antibodies for a retrovirus protein

Publications (2)

Publication Number Publication Date
WO2003062415A2 WO2003062415A2 (en) 2003-07-31
WO2003062415A3 true WO2003062415A3 (en) 2004-06-03

Family

ID=9929668

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/000653 WO2003062415A2 (en) 2002-01-24 2003-01-24 Transgenic animal comprising intracellular immunoglobins for xenotransplantation

Country Status (5)

Country Link
EP (1) EP1470222A2 (en)
AU (1) AU2003237975A1 (en)
CA (1) CA2474030A1 (en)
GB (1) GB0201611D0 (en)
WO (1) WO2003062415A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9399676B2 (en) 2013-05-06 2016-07-26 Scholar Rock, Inc. Compositions and methods for growth factor modulation
USRE49435E1 (en) 2014-11-12 2023-02-28 Seagen Inc. Glycan-interacting compounds and methods of use

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2846667B1 (en) * 2002-11-06 2004-12-31 Pasteur Institut VARIABLE FRAGMENTS OF SINGLE-CHAIN CAMELIDE ANTIBODIES DIRECTED AGAINST BETA-AMYLOID PEPTIDE 1-42 AND THEIR APPLICATIONS FOR DIAGNOSIS AND TREATMENT OF NEUROAGREGATIVE DISEASES
GB0522460D0 (en) * 2005-11-03 2005-12-14 Prendergast Patrick T Composition and method for the treatment of avian influenza
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN116217729A (en) 2015-11-12 2023-06-06 思进公司 Glycan interaction compounds and methods of use
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
EP3589319A4 (en) 2017-03-03 2021-07-14 Seagen Inc. Glycan-interacting compounds and methods of use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
COZZI E ET AL: "THE GENERATION OF TRANSGENIC PIGS AS POTENTIAL ORGAN DONORS FOR HUMANS", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 1, no. 9, September 1995 (1995-09-01), pages 964 - 966, XP001018786, ISSN: 1078-8956 *
DEKKER SYLVIA ET AL: "Intracellularly expressed single-domain antibody against p15 matrix protein prevents the production of porcine retroviruses.", JOURNAL OF VIROLOGY, vol. 77, no. 22, November 2003 (2003-11-01), pages 12132 - 12139, XP009025704, ISSN: 0022-538X (ISSN print) *
FIEBIG UWE ET AL: "Neutralizing antibodies against conserved domains of p15E of porcine endogenous retroviruses: Basis for a vaccine for xenotransplantation?", VIROLOGY, vol. 307, no. 2, 15 March 2003 (2003-03-15), pages 406 - 413, XP002269727, ISSN: 0042-6822 (ISSN print) *
HUANG JIAN ET AL: "Protection of xenographic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP.", FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, vol. 31, no. 3, October 2001 (2001-10-01), pages 203 - 209, XP002249602, ISSN: 0928-8244 *
MARIN MARIANA ET AL: "Antiviral activity of an intracellularly expressed single-chain antibody fragment directed against the murine leukemia virus capsid protein", HUMAN GENE THERAPY, vol. 11, no. 3, 10 February 2000 (2000-02-10), pages 389 - 401, XP002269728, ISSN: 1043-0342 *
VANHOVE B ET AL: "INTRACELLULAR EXPRESSION IN PIG CELLS OF ANTI-ALPHA1,3GALACTOSYLTRANS FERASE SINGLE-CHAIN FV ANTIBODIES REDUCES GALALPHA1,3GAL EXPRESSION AND INHIBITS CYTOTOXICITY MEDIATED BY ANTI-GAL XENOANTIBODIES", TRANSPLANTATION, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 66, no. 11, 15 December 1998 (1998-12-15), pages 1477 - 1485, XP001007737, ISSN: 0041-1337 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9399676B2 (en) 2013-05-06 2016-07-26 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US9573995B2 (en) 2013-05-06 2017-02-21 Scholar Rock, Inc. Compositions and methods for growth factor modulation
USRE49435E1 (en) 2014-11-12 2023-02-28 Seagen Inc. Glycan-interacting compounds and methods of use

Also Published As

Publication number Publication date
EP1470222A2 (en) 2004-10-27
AU2003237975A1 (en) 2003-09-02
GB0201611D0 (en) 2002-03-13
WO2003062415A2 (en) 2003-07-31
CA2474030A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
EP2123675A3 (en) Human EPO mimentic hinge core mimetibodies, compositions, methods and uses
EP1534066A4 (en) Alpha(1,3)-galactosyltransferase null cells, methods of selecting and alpha(1,3)-galactosyltransferase null swine produced therefrom
WO2002012501A3 (en) Anti-dual integrin antibodies, compositions, methods and uses
AU2001254624A1 (en) Human coagulation factor vii variants
WO2004003147A3 (en) Cngh0004 polypeptides, antibodies, compositions, methods and uses
WO2006119115A3 (en) Anti-il-6 antibodies, compositions, methods and uses
TW428026B (en) Bifunctional protein, preparation and use
O'Connor et al. Advances in identifying archaeological traces of horn and other keratinous hard tissues
EP2281876A3 (en) Methods for controlling pests using RNAi
WO2004002417A3 (en) Mammalian ch1 deleted mimetibodies, compositions, methods and uses
WO2002081490A3 (en) Computer-directed assembly of a polynucleotide encoding a target polypeptide
WO2008117125A3 (en) Compositions capable of facilitating penetration across a biological barrier
WO2003062415A3 (en) Transgenic animal comprising intracellular immunoglobins for xenotransplantation
WO2003089580A3 (en) Cancer models
DE10347218A1 (en) Sunscreens
DE60122562D1 (en) NUCLEIC ACIDS CODED FOR STICHODACTYLIDAE CHROMOPROTEINS
AU2001233917A1 (en) Bcmp-7 as marker for diagnosis of breast cancer
EP1760155A3 (en) Non-human sperm-DNA complexes for geneticallly modifying non-human animals
IL174726A (en) Nonhuman animal comprising transgenic nucleic acid sequence coding for mutant presenilin 1 protein
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells
WO2002049422A3 (en) Non-human animal disease models
WO2004087929A3 (en) Plants having improved growth characteristics and a method for making the same
WO2003060092A3 (en) Modified fatty acid hydroxylase protein and genes
EP2272527A3 (en) Combined DNA vaccine and biological modifiers for cancer therapy
WO1998031707A3 (en) Transgenic animals with disrupted npy y1 receptor genes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10894194

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2474030

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003731802

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003731802

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2003731802

Country of ref document: EP